Dr Reddy's gains Indian rights to Oceana's Deflux

18 May 2011

Privately-held US company Oceana Therapeutics, which is focused on acquiring, developing and commercializing best-in-class specialty therapeutics, has entered into a multi-year exclusive agreement with Indian pharmaceutical firm Dr Reddy’s Laboratories(NYSE:RDY), giving rights to the sale and distribution of Deflux in India. Further terms of the transaction were not disclosed.

Deflux consists of two types of sugar-based molecules (polysaccharides): dextranomer microspheres and hyaluronic acid of non-animal origin. The implant is stable long term, remains in position and does not disappear over time. Oceana Therapeutics acquired exclusive worldwide sales and distribution rights to Deflux in June 2009 from Sweden’s Q-Med AB.

Deflux is used for the treatment of vesicoureteral reflux (VUR) - a malformation of the urinary bladder which affects children and can result in severe infections of the kidney and even irreversible kidney damage.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK